Israeli Start-Up Alcobra Develops New Treatment for Attention Deficit Disorder

December 2, 2013 3:26 pm 2 comments
Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israel's Alcobra Pharmaceuticals has a new non-stimulant treatment for ADHD.

Israeli pharmaceutical start-up Alcobra Pharmaceuticals is listed on the NASDAQ electronic stock exchange under the ticker ADHD, the disease it treats with a non-stimulant compound that is expected to come to the market in 2015.

In an interview with Israeli business daily Globes, CEO Dr. Yaron Daniely explained how the company was originally created in 2008 to develop the molecule metadoxine to help inhibit the effects of alcohol on the brain.

“The goal was to create a pill that would quickly reduce blood alcohol levels, so that people would be able to drive safely,” explains Daniely. “It turned out the drug had no significant impact on removing alcohol from the blood, but it had a very significant impact on cognitive ability. In driving, memory, and attention tests that were conducted, it was as though those people were not drunk, despite the fact that, in terms of the amount of alcohol in their blood, it was not clear that they would be able to stand on their own two feet. So the idea to treat Attention Deficit Disorder came about.”

A pilot the company conducted in 2010 among 40 adults with ADHD showed “an immediate and significant improvement in attention tests. As a result of this, the company reinvented itself,” Daniely said, which is when he was named by researchers Dr. Dalia Megiddo and Udi Gilboa to be its new CEO.

Bilingual with a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine, an NIH Visiting Fellow in Cell Biology, a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science, in Rehovot, and an MBA from the Technion – Israel Institute of Technology, Daniely also was VP Business Development at Gamida Cell Ltd., managing its joint venture with Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) to develop a cancer drug.

The idea was to approach TEVA to fund the start-up, which it did with $5 million to fund its first tests. But with TEVA later in a management crisis, and its options to increase its position in Alcobra expired, the team sought an IPO on the NASDAQ, which has since net it some $60 million in proceeds and a market capitalization of $220 million, more than enough to fund its final tests and market launch.

Daniely said the chemical compound metadoxine has been approved for 40 years for the treatment of liver disease in third-world countries, including India, China, Russia, and Thailand. The company has registered a patent for the use of metadoxine for neurological conditions, through a timed-release of the substance, so its effect on the patient lasts a few hours.

Globes said that Alcobra has no labs, its raw materials are manufactured by a third party in Germany, and the pills themselves are manufactured in the US. The company believes that the drug combines the benefits of the two existing classes of ADHD drugs – the stimulants, such as Ritalin and Concerta, and the non-stimulant drugs, such as Strattera – and claims that it does not have their drawbacks.

According to the company, the results of the clinical trials showed that the drug is not addictive, worked faster and was twice as effective as the existing non-stimulant drugs, and had a similar anti-ADHD effect to that of the stimulants. It primarily affects cognitive ability, less so hyperactivity.

Daniely advised other Israeli start-ups to follow four lessons from Alcobra’s successful IPO. “The first element was quality, and a refusal to compromise,” he said. “Alcobra, from day one, tried to be different from other companies. We have an almost pedantic stubbornness not to do things too small or too short, but rather to do the things the way we would if we were a company in Silicon Valley. Therefore, our Phase II trial didn’t include 20 people over two weeks, instead, it included 120 people, with a placebo control, over the course of six weeks, using the exact same measures that all the ADHD drugs in the world are measured by. Many companies understand too late that they are conducting poorer trials without the appropriate controls.”

The second element was the company’s target market. “There’s nothing like ADHD,” he says. “First of all, people understand the market; there are drugs, it is known how much each company is selling and why, there are patients, there is a market that turns over $4 billion each year in the US. Also, people think they understand what ADHD is. It affects almost everyone, their kid, or their nephew.”

A third element is the pace of development: “With ADHD, unlike rare cancers, participants for clinical trials are incredibly easy to find. So our time to market and our ability to build our development process are such that almost every month we have good news for shareholders. The phase III trial will include 300 patients, in 20 medical centers, over the course of six months.”

The fourth element that helped secure funding was his native-English speaking ability, personal CV and track record and a decision to invite well-known professionals from the ADHD research community to be on their team, in this case, Prof. Lenard Adler, a researcher from NYU and an expert in ADHD drug development, who serves as head of the clinical committee that advises the company. “When someone like him sits next to you and says: ‘I conducted the trial and I stand behind the results,’ they can’t blow you off. Israeli entrepreneurs need to understand this and bring these people to their companies, so they can bridge the gap,” Daniely said.

While the company tried to get funding in Israel, where ADHD is less frequently diagnosed, its success in raising money on the NASDAQ has led many other young pharma companies to its doors, seeking advice. Its success has also led to new projects.

“Many things happened at the company, and our ability to implement plans grew. We had a tremendous opportunity to treat fragile X syndrome, which is associated with autism. It is a very common condition, which is very difficult for many who suffer from it, and there is no treatment. In a trial we conducted on animals with a kind of fragile X, we came up with outstanding results. It completely normalized learning, memory, social behavior, and communication. In parallel, the market in the US was still on fire, and said, ‘go, secure the investment, and bring in more cash,’” Daniely said.

The funds Alcobra raised guarantee that the company will have full funding until it is approved as a drug for adult ADHD, which, according to Daniely, is expected to reach market in late 2015, and for children soon afterwards. The money will also fund the fragile X trial.

2 Comments

  • In this period of financial crisis, you usually do not have to spend huge amount of money just to find out girls
    get their clothes off in front individuals. You have to discover once the nude models from the sex chat website can be extremely beautiful and
    deliciously attractive. Military husbands stationed in the Middle
    East have been in a position to witness the birth of an youngster through webcams.

  • Davida Rosenberg

    Please update me when this will be available in the U.S.
    A family member age 36 male.. has suffered his whole young life with this condition.

Leave a Reply

Please note: comments may be published in the Algemeiner print edition.


Current day month ye@r *

More...

  • Arts and Culture Middle East Hamas Commander Reportedly Urges Hezbollah to Join Forces Against Israel

    Hamas Commander Reportedly Urges Hezbollah to Join Forces Against Israel

    JNS.org – Five months after Israeli forces tried to assassinate Hamas military commander Mohammed Deif in Gaza, Deif appears to have signed a letter that the terrorist group claims he wrote in hiding. The letter, addressed to Hezbollah chief Hassan Nasrallah, expressed Deif’s condolences for the death of Hezbollah terrorists during Sunday’s reported Israeli airstrike in Syria. Deif is said to have survived multiple assassination attempts, but he has not been seen in public for years. According to the Hezbollah-linked Al-Manar [...]

    Read more →
  • Jewish Identity Theater Shlomo Carlebach Musical Has the Soul to Heal Frayed Race Relations

    Shlomo Carlebach Musical Has the Soul to Heal Frayed Race Relations

    JNS.org – The cracks that had been simply painted over for so long began to show in Ferguson, Mo., in November 2014, but in truth they had begun to open wide much earlier—on Saturday, July 13, 2013. That is when a jury in Sanford, Fla., acquitted George Zimmerman of culpability for the death of a 17-year-old black man, Trayvon Martin. The cracks receded from view over time, as other news obscured them. Then came the evening of Aug. 9, 2014, [...]

    Read more →
  • Theater US & Canada ‘Homeland’ Season Finale Stirs Controversy After Comparing Menachem Begin to Taliban Leader

    ‘Homeland’ Season Finale Stirs Controversy After Comparing Menachem Begin to Taliban Leader

    A controversial scene in the season finale of Homeland sparked outrage by comparing former Israeli Prime Minister Menachem Begin to a fictional Taliban leader, the UK’s Daily Mail reported. In the season 4 finale episode, which aired on Dec. 21, CIA black ops director Dar Adal, played by F. Murray Abraham, justifies a deal he made with a Taliban leader by referencing Begin. He makes the remarks in a conversation with former CIA director Saul Berenson, a Jewish character played by Mandy [...]

    Read more →
  • Arts and Culture Spirituality/Tradition Placing Matisyahu Back Within a Life of Observance

    Placing Matisyahu Back Within a Life of Observance

    Shining Light on Fiction During the North Korea-Sony saga, we learned two important lessons. The first is that there are two sides to this story, and neither of them are correct because ultimately we should have neither inappropriate movies nor dictators. The second is that we cannot remain entirely fixed on the religious world, but we also must see beyond the external, secular view of reality. It’s important to ground our Torah-based thoughts into real-life activism. To view our act [...]

    Read more →
  • Arts and Culture Blogs Nine Decades of Moses at the Movies

    Nine Decades of Moses at the Movies

    JNS.org – Hollywood has had its share of big-budget biblical flops, but until now, the Exodus narrative has not been among them. Studios have brought Moses to the big screen sparingly, but in ways that defined the image and character of Moses for each generation of audiences. The first biblical epic In 1923, director Cecil B. DeMille left it to the American public to decide the subject of his next movie for Paramount. DeMille received a letter from a mechanic [...]

    Read more →
  • Arts and Culture Blogs Exodus on Screen (REVIEW)

    Exodus on Screen (REVIEW)

    JNS.org – The story of the Exodus from Egypt is a tale as old as time itself, to borrow a turn of phrase. It’s retold every Passover, both at the seder table and whenever “The Ten Commandments” is aired on television. But the latest adaptation—Ridley Scott’s epic film, “Exodus: Gods and Kings”—fails to meet expectations. Scott’s “Exodus” alters the source material to service the story and ground the tale, but the attempt to reinvent the biblical narrative becomes laughable. Moses [...]

    Read more →
  • Jewish Identity Lifestyle ‘Jewish Food Movement’ Comes of Age

    ‘Jewish Food Movement’ Comes of Age

    JNS.org - In December 2007, leaders of the Hazon nonprofit drafted seven-year goals for what they coined as the “Jewish Food Movement,” which has since been characterized by the increased prioritization of healthy eating, sustainable agriculture, and food-related activism in the Jewish community. What do the next seven years hold in store? “One thing I would like to see happen in the next seven years is [regarding] the issue of sugar, soda, and obesity, [seeing] what would it be like to rally the [...]

    Read more →
  • Blogs Education Seeds of ‘Start-Up Nation’ Cultivated by Israel Sci-Tech Schools

    Seeds of ‘Start-Up Nation’ Cultivated by Israel Sci-Tech Schools

    JNS.org – Forget the dioramas. How about working on an Israeli Air Force drone? That’s exactly the kind of beyond-their-years access enjoyed by students at the Israel Aerospace Industries (IAI) industrial vocational high school run by Israel Sci-Tech Schools, the largest education network in the Jewish state. More than 300 students (250 on the high school level and 68 at a two-year vocational academy) get hands-on training in the disciplines of aviation mechanics, electricity and energy control, and unmanned air [...]

    Read more →



Sign up now to receive our regular news briefs.